Elanco Animal Health Reports Second Quarter 2026 Results
Elanco reported Q2 revenue of $1.37 billion, up 10% year-over-year, with adjusted EPS growing 31% to $0.34 driven by strong demand in the pet health segment. The company raised its full-year 2026 revenue outlook to $5.09 billion to $5.14 billion and increased adjusted EPS guidance to $1.10 to $1.16, citing faster-than-planned margin expansion.
Key figures
- Eps
- 0.34
- Revenue
- $1,368 million
- Guidance
- FY26 revenue $5.09B-$5.14B, Adj EBITDA $1.01B-$1.035B, Adj EPS $1.10-$1.16
- Revenue Yoy
- 10%
- Ebitda
- 288000000
- Ebitda margin
- 21.2%
- Net leverage ratio
- 3.1x
- Innovation revenue target
- $1.25 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.